Vivaldi BioSciences Obtains $23,000,000 Series A Funding Round

  • Feed Type
  • Date
    1/8/2009
  • Company Name
    Vivaldi BioSciences
  • Mailing Address
    750 Battery Street San Francisco, CA 94111
  • Company Description
    The company is developing influenza-targeted vaccines and therapeutics.
  • Website
    Undisclosed
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $23,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Vivaldi intends to use the proceeds from the Series A financing to establish cell-based manufacturing and to file an Investigational New Drug (IND) application to advance its lead vaccine candidate to clinical trials.
  • M&A Terms
  • Venture Investor
    Bay City Capital
  • Venture Investor
    NGN Capital
  • Venture Investor
    New York City Investment Fund
  • Venture Investor
    Alexandria Real Estate Equities, Inc.

Trending on Xconomy